Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report.

MedStar author(s):
Citation: Frontiers in Oncology. 13:1134151, 2023.PMID: 36998440Institution: MedStar Washington Hospital CenterDepartment: Hematology & Oncology Fellowship | Internal Medicine Residency | MedStar Georgetown University Hospital/MedStar Washington Hospital CenterForm of publication: Journal ArticleMedline article type(s): Case ReportsSubject headings: Year: 2023ISSN:
  • 2234-943X
Name of journal: Frontiers in oncologyAbstract: Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B-RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment. Copyright © 2023 Arora, Zaemes, Ozdemirli and Kim.All authors: Arora A, Zaemes J, Ozdemirli M, Kim CFiscal year: FY2023Digital Object Identifier: Date added to catalog: 2023-06-26
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 36998440 Available 36998440

Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a KIF5B-RET fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment. Copyright © 2023 Arora, Zaemes, Ozdemirli and Kim.

English

Powered by Koha